Quazi Ataher | Director, Epidemiology

Quazi Ataher, Director, Epidemiology, Pfizer

Quazi Ataher is a Senior Director of Epidemiology in Worldwide Safety Strategy at Pfizer. He is the Epidemiology Group Lead for Pfizer Essential Health and Pfizer Consumer Health businesses. He leads a group of epidemiologists responsible for developing and executing pharmacoepidemiology programs to support pharmacovigilance. Additionally he is involved in assessment and utilization of newer quantitative methods of product benefit-risk assessment at Pfize


Drug Safety World Day 2 @ 14:20

Aligning Pragmatic Multicriteria Decision Analysis (MCDA) and advanced pharmacoepidemiology in benefit-risk assessments to real-life regulatory constraints

  • Developing features of pragmatic MCDA EVIDEM [Evidence and Value: Impact on DEcisionMaking] 
  • Addressing real-life regulatory decision-making needs with adaptable decision analysis models
  • Successfully testing the efficacy of benefit risk frameworks through the incorporation of advanced pharmacoepidemiology

Drug Safety World Day 2 @ 15:20

Structured benefit-risk assessments – How different pharmaceutical companies are implementing new FDA guidance

  • Regulatory and industry experiences with approaches to structured benefit-risk assessments 
  • Approaches to incorporating patient perspectives into structured benefit-risk assessment 
  • Exploring available methods to advance structured benefit-risk assessment

back to speakers